Alkermes (ALKS) Accounts Payables (2011 - 2026)
Alkermes (ALKS) posted quarterly Accounts Payables of $332.5 million for Q2 2026, up 35.29% year-over-year from $245.7 million in Q2 2025, and up 13.63% quarter-over-quarter from $292.6 million in Q1 2026.
Alkermes (ALKS) Accounts Payables (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Accounts Payables for 16 consecutive years, with $332.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Accounts Payables rose 35.29% year-over-year to $332.5 million; the TTM figure through Jun 2026 stood at $332.5 million (up 35.29% YoY), while the FY2025 annual figure was $289.6 million, up 56.24% from the prior year.
- Accounts Payables grew to $332.5 million in Q2 2026 per ALKS's latest filing, from $292.6 million in the prior quarter.
- Across five years, Accounts Payables topped out at $332.5 million in Q2 2026 and bottomed at $160.2 million in Q3 2024.
- Historically, Accounts Payables has averaged $225.6 million across 5 years, with a median of $217.5 million in 2022.
- Annual changes were most pronounced in 2022 — Accounts Payables tumbled 50.66% — and 2026, when it jumped 57.27%.
- Alkermes' Accounts Payables stood at $220.1 million in 2022, then gained by 9.3% to $240.6 million in 2023, then fell by 22.96% to $185.3 million in 2024, then soared by 56.24% to $289.6 million in 2025, then grew by 14.82% to $332.5 million in 2026.
- Business Quant data shows ALKS's Accounts Payables at $332.5 million in Q2 2026, $292.6 million in Q1 2026, and $289.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -5.09 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 452.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 356.00 Mn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 332.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 332.47 Mn |
| Mar 31, 2026 | 292.58 Mn |
| Dec 31, 2025 | 289.57 Mn |
| Sep 30, 2025 | 214.99 Mn |
| Jun 30, 2025 | 245.75 Mn |
| Mar 31, 2025 | 186.04 Mn |
| Dec 31, 2024 | 185.33 Mn |
| Sep 30, 2024 | 160.20 Mn |
| Jun 30, 2024 | 239.77 Mn |
| Mar 31, 2024 | 205.85 Mn |
| Dec 31, 2023 | 240.56 Mn |
| Sep 30, 2023 | 243.26 Mn |
| Jun 30, 2023 | 242.92 Mn |
| Mar 31, 2023 | 190.15 Mn |
| Dec 31, 2022 | 220.09 Mn |
| Sep 30, 2022 | 211.18 Mn |
| Jun 30, 2022 | 186.81 Mn |
| Mar 31, 2022 | 173.13 Mn |
| Dec 31, 2021 | 208.49 Mn |
| Sep 30, 2021 | 428.03 Mn |